Needham & Company Reiterates Buy on Sequans Communications (SQNS) Following Equity Offering
- Futures edge lower as focus turns to Fed meeting
- BOJ hikes interest rates for first time in 17 years, to remain accommodative
- Buy the dip in US stocks in case of a 'rate shock' - Goldman
- Shares dip, yen slides as BOJ's landmark policy shift draws eyes
- Nvidia unveils Blackwell, AI chip 'to power this new industrial revolution'
- Canoo Inc. (GOEV) Provides Update on $62M Share Pre-Paid Advance Agreement
- StoneCo (STNE) Tops Q4 EPS by 33c
- JOANN Inc (JOAN) Enters Agreement to Reduce Debt and Receive $132 Mln in New Capital
- Super Micro Computer (SMCI) Announces Proposed 2M Share Offering
- Cisco Systems (CSCO) Completes Acquisition of Splunk (SPLK)
Unusual 11 Mid-Day Movers 9/15: (AERI) (CLBS) (CBR) Higher; (UUUU) (ACST) (UWN) Lower
September 15, 2016 12:51 PM EDTAerie Pharmaceuticals, Inc. (Nasdaq: AERI) 51.0% HIGHER; reported the successful 90-day primary efficacy results of its 12-month Phase 3 Mercury 1 clinical trial for its fixed-dose combination product candidate, Roclatan. The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening.
Energy Fuels Inc. (NYSE: UUUU) 22.9% LOWER; announced that due to increased demand, it... More
Pre-Open Stock Movers 09/15: (AERI) (ACRX) (NTWK) Higher; (SQNS) (PAH) (SRPT) Lower (more...)
September 15, 2016 9:30 AM EDTAerie Pharma (NASDAQ: AERI) 65% HIGHER; reported the successful 90-day primary efficacy results of its 12-month Phase 3 Mercury 1 clinical trial for its fixed-dose combination product candidate, Roclatan. The study achieved its primary efficacy endpoint demonstrating statistical superiority over each of its components, including Aerie product candidate Rhopressa (netarsudil ophthalmic solution) 0.02%, and market leading prostaglandin analogue (PGA) latanoprost, all of which were dosed once daily in the evening.
Sequans Communications S.A.... More
Sequans Communications (SQNS) Prices 15.15M ADS Offering for Net Proceeds of $22.9M
September 15, 2016 9:03 AM EDTSequans Communications S.A. (NYSE: SQNS) announced the pricing of an underwritten public offering of American Depositary Shares (ADSs), representing 15,151,520 ordinary shares, at a price of $1.65 per ADS, in an underwritten public offering under an effective shelf registration statement (the Offering) filed with the Securities and Exchange Commission (the SEC). The Company has also granted to the underwriters a 30-day option to acquire an additional 2,272,728 ADSs to cover overallotments, if any, in connection with the Offering. After... More